Alzheimer's disease Other Imaging Findings: Difference between revisions
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to assess for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease. On SPECT scan patients with Alzheimer's disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices. | Other [[imaging]] studies in Alzheimer's include [[positron emission tomography]] ([[PET]]) and [[single photon emission computed tomography]] ([[SPECT]]) scan. [[PET scan|PET]] and [[SPECT]] scan are not routinely done in Alzheimer's disease. However, [[patients]] with atypical presentation may be evaluated with either a [[PET scan|PET]] or [[SPECT]] scan to assess for any underlying condition. In these patients, use of [[Amyloid beta|amyloid β]] [[PET scan|PET]] scan will reveal lower [[FDG]] (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the [[brain]] affected by Alzheimer's disease. On [[SPECT]] scan patients with Alzheimer's disease have low relative regional [[cerebral blood flow]] (rCBF) in the [[parietal]] and [[Prefrontal cortex|prefrontal]] cortices. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
* Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. | * Other [[imaging]] studies in Alzheimer's include [[positron emission tomography]] ([[PET scan|PET]]) and [[single photon emission computed tomography]] ([[SPECT]]) scan. | ||
* PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition. | * [[PET scan|PET]] and [[SPECT]] scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a [[PET scan|PET]] or [[SPECT]] scan to further assess the patient for any underlying condition. | ||
* The Amyloid Imaging Taskforce (AIT) recommends use of amyloid β (Aβ) positron emission tomography (PET) scanning in atypical cases of Alzheimer's. | * The Amyloid Imaging Taskforce (AIT) recommends use of [[Amyloid beta|amyloid β]] ([[Aβ]]) [[positron emission tomography]] ([[PET]]) scanning in atypical cases of Alzheimer's. | ||
* The tracer used in PET scan for amyloid β include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose(FDG). | * The [[tracer]] used in [[PET scan|PET]] scan for [[Amyloid beta|amyloid β]] include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose([[FDG]]). | ||
* Patients with atypical presentation of Alzheimer's and a greater decline in memory function will have lower FDG metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease. | * Patients with atypical presentation of Alzheimer's and a greater decline in [[memory]] function will have lower [[FDG]] metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease. | ||
* According to the guidelines of AIT, amyloid β PET scan is recommended in cases of: | * According to the guidelines of AIT, [[Amyloid beta|amyloid β]] [[PET scan|PET]] scan is recommended in cases of: | ||
** Patients with persistent or progressive unexplained mild cognitive impairment | ** Patients with persistent or progressive unexplained [[mild cognitive impairment]] | ||
** Patients with early age onset | ** Patients with early age onset | ||
** Patients with progressive dementia | ** Patients with progressive [[dementia]] | ||
* In SPECT scan, patients are given a simple word-discrimination task and then observed for gradation of cerebral blood flow (rCBF). | * In [[SPECT]] scan, patients are given a simple word-discrimination task and then observed for gradation of regional [[cerebral blood flow]] (rCBF). | ||
* Patients with Alzheimer disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices. | * Patients with Alzheimer disease have low relative regional [[cerebral blood flow]] (rCBF) in the [[parietal]] and [[Prefrontal cortex|prefrontal]] cortices. | ||
==References== | ==References== |
Revision as of 14:20, 21 September 2017
Alzheimer's disease Microchapters |
Diagnosis |
---|
Treatment |
Alzheimer's disease Other Imaging Findings On the Web |
American Roentgen Ray Society Images of Alzheimer's disease Other Imaging Findings |
Risk calculators and risk factors for Alzheimer's disease Other Imaging Findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to assess for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease. On SPECT scan patients with Alzheimer's disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices.
Other Imaging Findings
- Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan.
- PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition.
- The Amyloid Imaging Taskforce (AIT) recommends use of amyloid β (Aβ) positron emission tomography (PET) scanning in atypical cases of Alzheimer's.
- The tracer used in PET scan for amyloid β include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose(FDG).
- Patients with atypical presentation of Alzheimer's and a greater decline in memory function will have lower FDG metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease.
- According to the guidelines of AIT, amyloid β PET scan is recommended in cases of:
- Patients with persistent or progressive unexplained mild cognitive impairment
- Patients with early age onset
- Patients with progressive dementia
- In SPECT scan, patients are given a simple word-discrimination task and then observed for gradation of regional cerebral blood flow (rCBF).
- Patients with Alzheimer disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices.